J&J Risperdal Off-Label Settlement Includes Exec Pay Recoupment Provision
This article was originally published in The Pink Sheet Daily
Janssen subsidiary pleads guilty as part of $2.2 billion deal that also requires audits of sales rep compensation.
You may also be interested in...
Corporate integrity agreement attached to second DOJ settlement over repackaging of injectable cancer drugs would require recoupment of exec performance pay following misconduct.
A look at the settlement agreements pharma companies have struck with the Department of Justice in the last three years; the size of the deals has declined dramatically since 2012.
In case that could impact use of state unfair trade practices statutes, Janssen seeks Supreme Court review of South Carolina’s $124 million judgment for Risperdal labeling and Dear Doctor letter.